Clinical Trials Browser

Interventional × Stomach Neoplasms × Pemetrexed × Clear all

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03061058 2017-09-15

Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

Phase 3 Unknown

240 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01953419 2016-07-28

Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy

Phase 2 Completed

34 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01172028 2015-12-03

Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

33 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male

NCT00415168 2010-08-17

Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer

Phase 2 Completed

53 enrolled 13 charts

Gastrointestinal

Stomach Neoplasms

NCT00320515 2009-09-28

Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer

Phase 1/2 Completed

89 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

Clinical Trials

PIVOT-02

Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy

Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer

Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer